Cogent Biosciences, Inc.

COGT

NASDAQHealthcareBiotechnology

Open in GoAI

Latest quote

$36.72

+$1.42 · +4.02%

Aug 21, 3:55 PM ET

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

51/100

GoAI score

Hold

Wait — insufficient conviction to act

Valuation

Expensive

Momentum

Gaining

Sentiment

Bullish

Risk resilience

Moderate Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Cogent Biosciences, Inc. is a biotechnology firm dedicated to creating targeted treatments for illnesses rooted in specific genetic anomalies. The company's primary therapeutic candidate is CGT9486, a selective tyrosine kinase inhibitor engineered to block the KIT D816V mutation, a key driver of systemic mastocytosis, along with other KIT exon 17 mutations observed in individuals suffering from advanced gastrointestinal stromal tumors (GIST). Furthermore, Cogent holds a licensing pact with Plexxikon Inc., granting it rights for the investigation, advancement, and marketing of bezuclastinib. Previously known as Unum Therapeutics Inc., the company adopted its current name, Cogent Biosciences, Inc., in October 2020. Established in 2014, Cogent Biosciences is headquartered in Cambridge, Massachusetts.

Industry: Biotechnology
Sector: Healthcare
Headquarters: US
CEO: Andrew R. Robbins
Listed since: Mar 29, 2018
Employees: 258

Market position

Volume: 2.52M; 1.12× average
Average volume: 2.24M; Average daily volume
Market cap: 6.28B USD
Beta: 0.33; Market reference 1

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value: 5.66B USD
P/E (TTM): -15.9×
P/B (TTM): 11.8×
P/S (TTM): 0×
EV / EBITDA: -17.62×
Earnings yield: -5.75%
Free cash flow yield: -4.65%
Dividend yield: 0.00%

Profitability & efficiency

Gross margin: 0.00%
Operating margin: 0.00%
Net margin: 0.00%
Return on equity: -51.69%
Return on assets: -35.08%
Return on invested capital: -38.09%

Financial health

Debt / equity: 0.46×
Current ratio: 14.23×
Altman Z-score: 9.73
Piotroski F-score: 2 of 9

Financial statements

Income trends

Operating income

−333.36M USD-20.81%

Net income

−328.94M USD-28.56%

Metric (USD)	FY2025	FY2024	FY2023	FY2022	FY2021
Cost of goods sold	4.62M USD	—	—	—	—
Gross profit	−4.62M USD	—	—	—	—
Research and development	269.78M USD	232.66M USD	173.76M USD	121.63M USD	55.91M USD
Selling, general, and administrative	63.58M USD	43.28M USD	34.38M USD	26.21M USD	19.64M USD
Operating expenses	328.74M USD	275.94M USD	208.13M USD	147.84M USD	75.55M USD
Interest income	14.69M USD	18.09M USD	13.08M USD	3.99M USD	467K USD
Interest expense	3.06M USD	—	—	3.99M USD	—
Depreciation and amortization	4.62M USD	4.35M USD	3.59M USD	5.88M USD	1.99M USD
Operating income	−333.36M USD	−275.94M USD	−208.13M USD	−147.84M USD	−75.55M USD
Net income	−328.94M USD	−255.86M USD	−192.41M USD	−140.24M USD	−72.27M USD